MARKET

AFMD

AFMD

Affimed
NASDAQ
0.7550
-0.1227
-13.98%
Closed 19:13 06/05 EDT
OPEN
0.8780
PREV CLOSE
0.8777
HIGH
0.8780
LOW
0.7411
VOLUME
1.90M
TURNOVER
--
52 WEEK HIGH
3.400
52 WEEK LOW
0.5502
MARKET CAP
112.75M
P/E (TTM)
-1.0239
1D
5D
1M
3M
1Y
5Y
HC Wainwright & Co. Maintains Affimed N.V. (AFMD) Buy Recommendation
NASDAQ · 6h ago
HC Wainwright & Co. Maintains Buy on Affimed, Lowers Price Target to $5
Benzinga · 18h ago
Affimed (AFMD) Receives a Buy from H.C. Wainwright
TipRanks · 19h ago
Why Mallinckrodt Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving Premarket
Benzinga · 20h ago
Affimed: Report of foreign issuer
Press release · 21h ago
HC Wainwright Trims Price Target on Affimed to $5 From $6, Maintains Buy Rating
HC Wainwright Trims Price Target on Affimed to $5 From $6, Maintains Buy Rating
MT Newswires · 22h ago
Affimed's Q1 2023 Analysis: Financial And Regulatory Challenges Persist
Seeking Alpha · 1d ago
BRIEF-Affirmed Says AFM24 Showed Clinical Activity In 7 Out Of 15 Heavily Pre-Treated Patients With Tumor Reductions
Reuters · 2d ago
More
About AFMD
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

Webull offers kinds of Affimed NV stock information, including NASDAQ:AFMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AFMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AFMD stock methods without spending real money on the virtual paper trading platform.